Clinical Trials Logo

Filter by:
NCT ID: NCT06424821 Recruiting - NSCLC Clinical Trials

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

LungCadX
Start date: July 4, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to investigate the efficacy, safety and tolerability of PD-1/CTLA-4 inhibitor (Cadonilimab) combination with chemotherapy as first-line treatment for PD-L1 negative advanced non small cell lung cancer patients. And also explore the potential biomarkers for predicting the efficacy of PD-1/CTLA-4 inhibitor for advanced non small cell lung cancer.

NCT ID: NCT06424665 Not yet recruiting - Clinical trials for Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.

NCT ID: NCT06424639 Not yet recruiting - Aplastic Anemia Clinical Trials

Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA

Start date: May 2024
Phase: Phase 4
Study type: Interventional

In a randomized, controlled clinical trial, the efficacy and safety of rodsipil combined with cyclosporine versus cyclosporine alone in the treatment of newly diagnosed non-transfusion-dependent NSAA were compared.

NCT ID: NCT06424626 Not yet recruiting - Melanoma Clinical Trials

A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma

Start date: May 21, 2024
Phase: Phase 1
Study type: Interventional

This study was a phase IB, single-center, open-label, two part(part A involved dose reduction, and part B involved cohort expansion) clinical trial evaluating the safety and clinical activity of AK104 or AK112 in combination with axitinib in patients with advanced mucosal melanoma.

NCT ID: NCT06424613 Recruiting - Bipolar Disorder Clinical Trials

Effects of Lithium on Suicide Prevention in Adolescents and Young Adults With Bipolar Disorder in China

Start date: April 18, 2024
Phase:
Study type: Observational

This study aims to use a retrospective cohort approach to explore the impact of lithium carbonate on suicide and self-harm related events among adolescents and young adults with bipolar disorder in China.The primary objective of this study is to investigate the effects of lithium carbonate on suicidal ideation in adolescents and young adults with bipolar disorder in China. Secondary objectives include exploring its effects on preventing suicide attempts, non-suicidal self-injury, and aggressive behaviors in this population.

NCT ID: NCT06424431 Completed - Pancreatectomy Clinical Trials

Methods of Pancreatic Stump Closure for Distal Pancreatectomy

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to conduct a retrospective analysis of patients who underwent distal pancreatectomy in our hospital, aiming to evaluate the safety and feasibility of two methods for closure of the pancreatic remnant: simple closure with a closure device and closure combined with electrocoagulation.

NCT ID: NCT06424405 Recruiting - Clinical trials for Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)

A New Objective Titration Procedure for the Treatment of Mandibular Advancement Device in OSAHS Patients

Start date: April 25, 2024
Phase: N/A
Study type: Interventional

The aim of this clinical trial is to apply a new objective titration procedure in obstructive sleep apnea hypopnea syndrome (OSAHS) patients treated with mandibular advancement device (MAD), and to compare this new objective titration procedure with the subjective titration procedure which is commonly used in clinical practice. The remotely intelligent sleep monitoring system (RISMS) will be used in the new objective titration procedure. The main questions it aims to answer are: 1. The efficacy of MAD therapy after each titration procedure. 2. The titration time efficiency and the improvement of subjective symptoms after each titration procedure.

NCT ID: NCT06424314 Not yet recruiting - Weaning Failure Clinical Trials

Exploration of Mechanisms for Weaning Failure

Start date: June 15, 2024
Phase:
Study type: Observational

This study is a prospective physiologic study. The primary study population will be adult invasive tracheal intubated patients with COPD, and investigators will collect relevant demographic data, vital signs, and baseline physiologic parameters of the patients prior to the spontaneous breathing test(SBT). The participants will be divided into a successful withdrawal group and a failed withdrawal group according to the SBT outcome, and the changes in the above parameters during SBT will be compared between the two groups .

NCT ID: NCT06424145 Enrolling by invitation - Clinical trials for Radial Artery Injury

Effect of Local Anesthesia Position of Lidocaine Injection on the Success Rate of Radial Artery Puncture Tube

Start date: June 30, 2024
Phase: N/A
Study type: Interventional

Objective: To investigate the effect of lidocaine injection location on the success rate of ultrasound-guided radial artery catheterization in a single-center, randomized, controlled clinical trial.

NCT ID: NCT06423937 Not yet recruiting - Colorectal Cancer Clinical Trials

Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

Start date: May 2024
Phase: Phase 2
Study type: Interventional

Liver metastasis is the main cause of death in patients with colorectal cancer. The treatment of liver metastasis of colorectal cancer is the key to prolong the survival of patients. The purpose of this study was to investigate the efficacy and safety of fruquintinib combined with Camrelizumab and HAIC regimen in the treatment of non-MSI-H advanced colorectal cancer patients with liver metastasis after first-line standard treatment failure. Compared with the current standard second-line treatment plan, it provides new decisions for clinical practice, in order to reduce the adverse reactions of treatment and improve the tolerance and efficacy of patients. To provide more and more optimized medication options for patients with non-MSI-H advanced colorectal cancer complicated with liver metastasis.